Editorial
Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice
Abstract
Final results from the randomised phase III METEOR study have been recently published and confirmed the superiority of cabozantinib over everolimus in patients with advanced or metastatic clear-cell renal cell carcinoma (mRCC) who received at least one previous VEGFR tyrosine-kinase inhibitor (TKI) (1).
